Cargando…

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions

Immune checkpoint inhibitors (ICIs) have demonstrated marked clinical effects worldwide, and “cancer immunotherapy” has been recognized as a feasible option for cancer treatment. Significant treatment responses have already been attained for malignant melanoma and lung cancer, ahead of gynecologic c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kagabu, Masahiro, Nagasawa, Takayuki, Sato, Chie, Fukagawa, Yasuko, Kawamura, Hanae, Tomabechi, Hidetoshi, Takemoto, Shuji, Shoji, Tadahiro, Baba, Tsukasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177858/ https://www.ncbi.nlm.nih.gov/pubmed/32230938 http://dx.doi.org/10.3390/ijms21072335

Ejemplares similares

Immunotherapy for Uterine Cervical Cancer
por: Kagabu, Masahiro, et al.
Publicado: (2019)

Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study
por: Kagabu, Masahiro, et al.
Publicado: (2021)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease
por: Shoji, Tadahiro, et al.
Publicado: (2019)

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023)

Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor
por: Kagabu, Masahiro, et al.
Publicado: (2023)

Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]
por: Takeuchi, Satoshi, et al.
Publicado: (2020)

A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass
por: Takatori, Eriko, et al.
Publicado: (2016)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass
por: Shoji, Tadahiro, et al.
Publicado: (2016)

Mast cells partially contribute to mucosal adjuvanticity of surfactin in mice
por: Yoshino, Naoto, et al.
Publicado: (2017)

Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma
por: Sato, Chie, et al.
Publicado: (2020)

Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer
por: Watanabe, Takafumi, et al.
Publicado: (2020)

Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers
por: Fukagawa, Daisuke, et al.
Publicado: (2018)

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports
por: Shoji, Tadahiro, et al.
Publicado: (2018)

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report
por: Takatori, Eriko, et al.
Publicado: (2015)

A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy
por: Shoji, Tadahiro, et al.
Publicado: (2020)

Cerebral diffusion kurtosis imaging to assess the pathophysiology of postpartum depression
por: Sasaki, Yuri, et al.
Publicado: (2020)

Mesenteric extraovarian Sertoli-Leydig cell tumor without DICER1 hotspot mutation: a case report
por: Osakabe, Mitsumasa, et al.
Publicado: (2019)

Changes of uterine blood flow after vaginal radical trachelectomy (VRT) in patients with early-stage uterine invasive cervical cancer
por: Umemura, Kota, et al.
Publicado: (2010)

Alternative Checkpoints as Targets for Immunotherapy
por: Pant, Ayush, et al.
Publicado: (2020)

Purification of cone outer segment for proteomic analysis on its membrane proteins in carp retina
por: Fukagawa, Takashi, et al.
Publicado: (2017)

Crystal Structure of an Archaeal Tyrosyl-tRNA Synthetase Bound to Photocaged L-Tyrosine and Its Potential Application to Time-Resolved X-ray Crystallography
por: Hosaka, Toshiaki, et al.
Publicado: (2022)

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
por: Kudo-Saito, Chie, et al.
Publicado: (2022)

Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy
por: Kawakami, Yutaka, et al.
Publicado: (2013)

Immune checkpoints and immunotherapy for colorectal cancer
por: Singh, Preet Paul, et al.
Publicado: (2015)

Immune checkpoint signaling and cancer immunotherapy
por: He, Xing, et al.
Publicado: (2020)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

Resistance to Checkpoint Inhibition in Cancer Immunotherapy
por: Barrueto, Luisa, et al.
Publicado: (2020)

Emerging phagocytosis checkpoints in cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015)

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
por: Rajani, Karishma R., et al.
Publicado: (2015)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer
por: Shevchenko, Ivan, et al.
Publicado: (2018)

Immune checkpoints, their control by immunotherapy and ovarian cancer
por: Bose, Chinmoy K.
Publicado: (2017)

Cancer immunotherapy: Moving beyond checkpoint inhibition
por: Boes, Marianne
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fkc9grr6miuo35sagko3plgkbl